CNS pharmacokinetics of antifungal agents.
The goal in treatment of infections is to achieve a beneficial effect while minimizing toxicity. It is widely recognized that the principles of pharmacokinetics and pharmacodynamics are critical to determining an adequate dose-response relationship. There has been an increased involvement of the CNS to infection from opportunistic and endemic fungi over the last several decades due to establishment of solid-organ and bone marrow transplantation as well as immunosuppression from HIV. In this regard it has become critical to define optimal dosing regimens by an understanding of the processes which govern delivery of an antifungal agent to the targeted CNS site of involvement. The objective of this review is to: i) summarize published experimental and clinical antifungal pharmacokinetics; and ii) examine the relationship between CNS antifungal pharmacokinetics and efficacy. Examination of these studies reveal marked variability among antifungal drugs with regard to cerebrospinal fluid and brain parenchymal penetration. Formal examination of the relationship between CNS antifungal pharmacokinetics and efficacy are limited. The few experimental studies available suggest that brain parenchymal kinetics is a superior predictor of antifungal efficacy than cerebrospinal fluid concentrations.
Kethireddy
Shravan
S
University of Wisconsin School of Medicine and Public Health, Madison 600 Highland Ave, H4/572, Madison, WI 53792, USA.
Andes
David
D
D000666:Amphotericin B / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D000818:Animals; D000935:Antifungal Agents / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics*; D002490:Central Nervous System / Q000378:metabolism*; D005437:Flucytosine / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D006801:Humans; D014230:Triazoles / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics
D000935:Antifungal Agents; D014230:Triazoles; D000666:Amphotericin B; D005437:Flucytosine